.png)
Dr. Reddy’s Laboratories has launched Toripalimab in India.
Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology
drug approved by various regulatory authorities around the world such as the
United States Food and Drug Administration (USFDA), European Medicines Agency
(EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others
for the treatment of adults with recurrent or metastatic nasopharyngeal
carcinoma (RM-NPC).
In 2023, the company entered into a license and
commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab.
Under this agreement, the company obtained exclusive rights to develop and
commercialise Toripalimab in 21 countries including India, South Africa, Brazil
and various countries in Latin America. Additionally, the agreement allows the
company to expand the scope of the license to cover Australia, New Zealand and
nine other countries.
With this launch by the company, India becomes the third
country in the world after China and the United States to receive access to
this next generation PD-1 inhibitor 1. The company will market it under the
brand name Zytorvi in India.
Dr. Reddy's Laboratories is a multinational pharmaceutical
company based in Hyderabad, Telangana in India. It manufactures and markets a
wide range of pharmaceuticals in India and overseas.
Source: Ace Equity
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
